B & B Medical Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$19,734	1
2024	Research	$3,930	1
2023	Research	$144,131	4
2022	Research	$20,845	2
2021	Research	$1,549,661	4
2020	Research	$68,640	26
2019	Research	$106,551	22

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca UK Limited $904,018 5 payments
AstraZeneca Pharmaceuticals LP $832,099 5 payments
Allergan Inc. $107,237 19 payments
GRT US Holding, Inc. $33,167 13 payments
Teva Pharmaceuticals USA, Inc. $33,135 17 payments
Dr.Reddy's Laboratories,Inc. $3,836 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061) for Pre-exposure Prophylaxis of COVID-19 $1,495,645 3 payments
A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 $139,735 3 payments
A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $107,237 19 payments
A Phase II Randomized Openlabel Multicenter Doseranging Study in Adults and Pediatric Individuals 2265 12 years of Age to Assess the Safety Immunogenicity Pharmacokinetics and Pharmacodynamics of AZD7442 a Combination Product of Two Monoclonal Antibodies Tixagevimab and Cilgavimab for Pre-exposure Prophylaxis of COVID19 $81,003 3 payments
Kf7013-04 $33,167 13 payments
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older $19,734 1 payment
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age $12,800 6 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age $12,385 8 payments
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age $7,950 3 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura $3,836 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.